Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PTHS by emailGet an email when PTHS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PTHS, unsubscribe in one click. Privacy
📣 What PTHS Says Is Next
Early 2027 · “Anticipated Commercial Launch: Early 2027 Pelthos Opportunity Acquired from BioFrontera in October 2025 FDA Approved in 2017 Exclusivity until 2032 1https://www.cdc.gov/group-a-strep/about/impetigo.html Xeglyze: New Product Acquisition 19 Xeglyze (abametapir) Lotion for the Treatment of Head Lice Sources: CDC Website, Xeglyze Pack Insert, FDA.gov”
Company press release, May 28, 2026 · SEC filing
mid-2027 · “Commercial launch expected in mid-2027 Experienced management team: Over 20 successful prior drug launches, including Cosentyx, Otezla, Ohtuvayre, Xifaxan 5 Management Team John M.”
Company press release, May 28, 2026 · SEC filing
Mid-2027 · “Anticipated Commercial Launch: Mid-2027 Pelthos Opportunity Acquired from Hatchtech in December 2025 FDA Approved in 2020 Exclusivity until 2034 1https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf Summary Financial Statements 2121 Summary Balance Sheet”
Company press release, May 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PTHS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PTHS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.